NasdaqCM - Nasdaq Real Time Price
USD
Psyence Biomedical Ltd. (PBM)
3.3100
0.0000
(0.00%)
As of October 30 at 4:00:00 PM EDT. Market Open.
Key Executives
Amounts are as of December 31, 2026 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Jody Aufrichtig
|
Co-Founder, Executive Chairman & CEO | 393.33k | -- | 1974 |
|
Mr. Warwick Ron Corden-Lloyd
|
CFO & Director | 293k | -- | 1980 |
|
Dr. Neil Maresky M.D.
|
Global Head of Clinical Development | 800k | -- | 1964 |
|
Ms. Taryn Vos
|
General Counsel | -- | -- | -- |
Psyence Biomedical Ltd.
121 Richmond Street West
Penthouse Suite 1300
Toronto, ON M5H 2K1
Canada
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 12
Description
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
Corporate Governance
Psyence Biomedical Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of
Institutional Shareholder Services (ISS)
Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
